Skip to main content
OpenTrials
Completed

NCT Number: NCT04213196

Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

This is a first-in-human, Phase I, single-dose escalation clinical trial conducted in Chinese healthy volunteers. The safety, tolerability, and PK of HSK21542 injection in healthy volunteers will be evaluated using a randomized, double-blind, placebo-controlled trial design

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Second Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females aged 18-45 years old (inclusive) at screening;
  • Male volunteers no less than 50 kg, or female volunteers no less than 45 kg, with body mass index [BMI] in the range of 18.0-27.0 kg/m2 (inclusive) at screening;
  • Healthy volunteers, as assessed by the investigator based on past medical history, comprehensive physical examination, vital signs, and specified tests and examinations.
  • Fully understand the nature, purpose, and potential benefits, inconveniences and risks of the trial. Understand the study procedure and voluntarily provide written informed consent.
  • Able to communicate with the investigator and to follow all requirements of the study, and willing to be admitted into the phase I clinical facility.

Exclusion criteria

  • Those who have suffered or are currently suffering from any clinical serious disease such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, hematology, immunology, psychiatry and metabolic abnormality or any other disease or physiological condition that can interfere with the results;
  • Physical examination, vital sign monitoring, ECG examination, chest anteroposterior and lateral radiographs, laboratory examination (including blood routine, urine routine, blood biochemistry, coagulation function, thyroid function, blood pregnancy (only for female subjects) during screening period, and the researcher judged that the abnormality had clinical significance;
  • People with positive hepatitis B surface antigen, positive hepatitis C antibody, positive Treponema pallidum antibody, or positive AIDS virus antibody test;
  • Patients with QTcF>450 ms in ECG examination during screening;
  • Allergic constitution: such as those who are allergic to two or more drugs and foods; Or those who are allergic to any ingredient in this product and auxiliary materials; (Auxiliary materials: glacial acetic acid, sodium acetate, water for injection)
  • Those who cannot tolerate venipuncture and/or have a history of blood and needle sickness;
  • Those who have drunk too much tea, grapefruit, coffee, caffeinated or grapefruit drinks for a long time (more than 8 cups a day, 1 cup=250mL);
  • Those who have a history of alcohol abuse within 3 months before screening, that is, those who drink more than 14 units of alcohol per week (1 unit=12 ounces or 360 mL of beer, 1.5 ounces or 45 mL of spirits with 40% alcohol content, 5 ounces or 150 mL of wine), or those who have positive alcohol breath test;
  • Volunteers with a positive urine nicotine test;
  • Volunteers with drug abuse or dependence, or with a positive urine drugs of abuse test;
  • Those who have used any prescription medicine, over-the-counter medicine, Chinese herbal medicine and health care products within 14 days
  • Blood donation or loss of blood > 450 mL within the past 3 months;
  • Participation in any clinical trials within the past 3 months;
  • Volunteers who plan to become pregnant within the next 6 months;
  • Any other factors judged by the investigator to be unsuitable for participating in this study.

Treatment and study plan

HSK21542

Drug

Intravenous injection 0.2 μg/kg solution (active or placebo, 0.5-1h after standard meal). Complete infusion within 15 min.

Other names: HSK21542 0.2 μg/kg

Primary outcomes

  1. AE/serious AE

    Time frame: From screening up to 3 weeks

    Adverse event/serious adverse event

  2. Vital signs: Systolic and Diastolic Blood Pressure

    Time frame: From screening up to 3 weeks

    Vital signs (Systolic and Diastolic Blood Pressure) will be collected in healthy volunteers.

  3. Ramsay sedation score

    Time frame: -60 minutes before administration until 24 hours after administration

    Ramsay sedation score will be collected

  4. Visual analog scale (VAS) addiction score

    Time frame: from administration to 24 hours after administration

    VAS addiction score will be collected

Secondary outcomes

  1. Peak concentration (Cmax)

    Time frame: -30 minutes before administration until 24 hours after administration

    Cmax(a measure of the body's exposure to HSK21542)will be calculated in healthy volunteers.

  2. Area under the concentration-time curve(AUC)

    Time frame: -30 minutes before administration until 24 hours after administration

    AUC(a measure of the body's exposure to HSK21542)will be calculated in healthy volunteers.

  3. Tmax

    Time frame: -30 minutes before administration until 24 hours after administration

    time to peak observed

  4. Total clearance

    Time frame: -30 minutes before administration until 24 hours after administration

    Total clearance

  5. Prolactin level

    Time frame: before administration until 24 hours after administration

    Prolactin level will be collected

  6. Antidiuretic hormone level

    Time frame: before administration until 24 hours after administration

    Antidiuretic hormone level will be collected

  7. Urine volume

    Time frame: before administration until 24 hours after administration

    Urine volume will be collected

Sponsors and collaborators

Lead sponsor

Sichuan Haisco Pharmaceutical Group Co., Ltd

Industry

Collaborators

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

Registry information

Official study title

A Phase I Clinical Study Evaluating the Safety, Tolerability and Pharmacokinetics of HSK21542 in Healthy Volunteers

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Dec 30, 2019
Registry last updated
Feb 22, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.